1434686-56-2

Upstream product

• 1349820-44-5 6-butyl-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one 
• 19828-71-8 4-butyl-3-(2-phenoxyethoxy)aniline 
• 1349820-40-1 N-(4-butyl-3-(2-phenoxyethoxy)phenyl)acetamide 
• 22932-84-9 N-(4-butyl-3-hydroxyphenyl)acetamide 
• 22932-83-8 N-(3-hydroxy-4-(1-hydroxybutyl)phenyl)acetamide 
• 28583-62-2 N-(4-butyryl-3-hydroxyphenyl)acetamide 
• 215949-61-4 3-acetamidophenyl butyrate 
• 621-42-1 meta-hydroxyacetanilide 
• 1349820-67-2 6-butyl-3-iodo-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one 
• 74-88-4 methyl iodide 

Relevant academic research and scientific papers

4(1H)-Quinolones Having Antimalarial Activity With Reduced Chemical Resistance

Provided are 4(1H)-quinolone derivatives effective in inhibiting or eliminating the viability of at least one of the stages in the life-cycle of the malarial parasite, and to show a reduced propensity to induce resistance to the compound by the target parasite. In particular, the compounds can be derivatives of phenoxyethoxy-quinolones, and including, but not only, 7-(2-phenoxyethoxy)quinolin derivatives. These compounds may be administered by themselves, with at least one other derivative compound, or with other antimalarial compounds, to an animal or human subject. The therapeutic compositions can be and formulated to reduce the extent of a Plasmodium infection in the recipient subject, or to reduce the likelihood of the onset or establishment of a Plasmodium infection if administered prior to the parasite contacting the subject. The therapeutic compositions can be formulated to provide an effective single dose amount of an antimalarial compound or multiple doses for administering over a period of time.